IGF Oncology Announces Targeted Cancer Drug Results

ST. PAUL, Minn.--(BUSINESS WIRE)--IGF Oncology, a St. Paul-based company, reported the publication of results of a study of its new targeted anti-cancer drug in a peer-reviewed scientific journal. The company’s drug is a modified version of a commonly used cancer chemotherapy drug, modified to be targeted much more specifically to cancer cells and to bypass healthy cells. The results in mice, which are reported in the June issue of Translational Research, show the drug is significantly more effective than the standard drug, methotrexate, even at 6-fold lower dose. The lower dose is expected to result in lower side effects. The study was carried out in collaboration with the University of Minnesota. The authors include Hugh McTavish, the founder of IGF Oncology, and Arkadiusz Dudek, Oncologist and Assoc. Professor of Medicine at the University of Minnesota.

Back to news